IGC Pharma, Inc.
ASE: IGCLive Quote
About IGC Pharma, Inc.
Healthcare
Biotechnology
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
📊 Fundamental Analysis
IGC Pharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -53.6% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -83.3%, which indicates that capital utilization is currently under pressure.
At a current price of $0.30, IGC currently sits at the 24th percentile of its 52-week range (Range: $0.24 - $0.50).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$28.53M
Trailing P/E
--
Forward P/E
-3.35
Beta (5Y)
0.31
52W High
$0.50
52W Low
$0.24
Avg Volume
371K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App